Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant vaccinia-CEA(6D)-TRICOM vaccine
- Development stage
- Phase 2
- Lead developer
- National Cancer Institute
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, Oncolytic Viruses → Oncolytic Therapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
A cancer vaccine consisting of a recombinant vaccinia virus vector encoding the tumor-associated antigen carcinoembryonic antigen (CEA) and a triad of costimulatory molecules—B7.1, ICAM‑1, and LFA‑3—collectively known as TRICOM. The vaccine is designed to stimulate the host immune system to mount a T-cell response against tumor cells expressing CEA. The inclusion of TRICOM enhances antitumor cytotoxic T lymphocyte responses compared to vaccines containing only CEA. It has been evaluated in clinical trials for patients with advanced solid tumors expressing CEA, demonstrating safety and immunogenicity with some evidence of clinical benefit[1][2][3][4][5].
- Other names
- CEA-TRICOMvaccinia-CEA(6D)-TRICOMrV (NYC)-CEANSC 710067NSC710067NSC-710067
02
Targets
CD80 (T-lymphocyte activation antigen CD80)CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)ICAM1 (Intercellular Adhesion Molecule 1)CD58 (Leukocyte function-associated antigen 3)
Beyond the preview
Go deeper on recombinant vaccinia-CEA(6D)-TRICOM vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant vaccinia-CEA(6D)-TRICOM vaccine.